AU Patent

AU2017202301B2 — Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension

Assigned to Mallinckrodt Hospital Products IP Unlimited Co · Expires 2018-04-26 · 8y expired

What this patent protects

The invention relates to methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) in patients scheduled to undergo treatment with nitric oxide inhalation, by excluding patients who have pre existing left ventricular dysfu…

USPTO Abstract

The invention relates to methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) in patients scheduled to undergo treatment with nitric oxide inhalation, by excluding patients who have pre existing left ventricular dysfunction.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017202301B2
Jurisdiction
AU
Classification
—
Expires
2018-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Mallinckrodt Hospital Products IP Unlimited Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.